Department of Genetics, Cell and Immunobiology, Semmelweis University.
Hospital of Hospitaller Brothers of St. John of God, Budapest, Hungary.
Curr Opin Rheumatol. 2018 Mar;30(2):197-206. doi: 10.1097/BOR.0000000000000483.
Persuasive statistics support the clinical observation that because of cardiovascular comorbidities patients with inflammatory joint disease die significantly earlier despite anti-inflammatory therapy.
The reason for this earlier death is multifactorial and involves a combination of a complex genetic background, environmental influences, classical cardiovascular risk factors and the impact of anti-inflammatory therapy. We will describe the importance of several new mechanisms, especially the diverse intercellular communication routes including extracellular vesicles and microRNAs that support the development of cardiovascular comorbidities.
The aim of this review is to give an updated overview about the known risk factors in the development of cardiovascular comorbidities with the latest insights about their mechanism of action. Furthermore, the impact of newly identified risk factors and significance will be discussed.
有说服力的统计学数据支持这样一种临床观察，即由于心血管合并症的存在，尽管接受了抗炎治疗，炎性关节病患者的死亡仍明显提前。
这种过早死亡的原因是多因素的，涉及复杂的遗传背景、环境影响、经典心血管危险因素以及抗炎治疗的影响。我们将描述几个新机制的重要性，特别是包括细胞外囊泡和 microRNAs 在内的多种细胞间通讯途径，这些途径支持心血管合并症的发展。
本综述的目的是提供关于心血管合并症发展的已知危险因素的最新概述，并深入了解其作用机制。此外，还将讨论新确定的危险因素的影响及其意义。
Zotero 插件